Clinical Outcomes of Taiwanese Patients with cT4 Oral Cavity Squamous Cell Carcinoma: Toward the Identification of the Optimal Initial Treatment Approach for cT4b Patients
- 312 Downloads
The National Comprehensive Cancer Network guidelines recommend that patients with oral cavity squamous cell carcinoma (OSCC) and cT4b disease should be either included in clinical trials or treated with a nonsurgical approach. However, surgery may be feasible in selected patients with adequate safety margins. Using the nationwide Taiwanese Cancer Registry Database, we examined the prognosis of cT4b OSCC patients in relation to their treatment approach.
Of the 18,910 patients with previously untreated first primary OSCC identified between 2004 and 2010, 492 (2.6 %) had cT4b tumors. Of them, 327 (66 %) received initial treatment with surgery, whereas 165 (34 %) were initially treated with a nonsurgical approach. Of the latter group, 78 patients subsequently underwent surgery. A 5-year disease-specific survival (DSS) ≥45 % was considered as a favorable outcome.
Better 5-year DSS and overall survival (OS) rates were observed in cT4b patients initially treated with surgery (vs. nonsurgery; DSS, 51 vs. 38 %; OS, 43 vs. 27 %, respectively, p < 0.001). Of the participants initially treated with surgery, patients with cN0–2 disease had better 5-year survival rates (DSS: cN0, 59 %; cN1, 53 %; cN2, 46 %; OS: cN0, 49 %; cN1, 50 %; cN2, 37 %) than those with cN3 disease (DSS: 0 %; OS: 0 %). Among cT4b patients who initially received a nonsurgical treatment, subjects who subsequently underwent surgery showed better outcomes.
Primary surgery is performed in approximately two-thirds of cT4b OSCC patients, with cN0–2 cases showing a good prognosis. Patients who initially received a nonsurgical approach can subsequently be treated with surgery and achieve favorable outcomes.
KeywordsOverall Survival National Comprehensive Cancer Network National Comprehensive Cancer Network Overall Survival Rate Oral Cavity Squamous Cell Carcinoma
This research was financially supported by Grant CIRPD1D0031 from the Chang Gung Medical Research Program. We are grateful to the Research Service Center for Health Information (Chang Gung University, Taiwan) for the valuable input in study design, data management, and statistical analysis. We also acknowledge the kind assistance of the Oral Cancer Advisory Group, National Health Research Institute, Taiwan.
The authors declare no conflict of interest.
- 2.Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.Google Scholar
- 3.Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010.Google Scholar
- 4.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Head and Neck Cancers, v.I.2015. http://www.nccn.org/.
- 5.Kreppel M, Amir Manawi NN, Scheer M, et al. Prognostic quality of the Union Internationale Contre le Cancer/American Joint Committee on Cancer TNM classification, 7th edition, for cancer of the maxillary sinus. Head Neck. 2015;37:400–6.Google Scholar
- 12.Cancer registry annual report, Taiwan, 2012. http://www.bhp.doh.gov.tw/.
- 13.Liao CT, Lin CY, Fan KH, Wang HM. The optimal treatment modality for Taiwan oral cavity cancer patients—experience of a medical center. J Cancer Res Pract. 2015;2:103–16.Google Scholar